Currently out of the existing stock ratings of Gil Blum, 219 are a BUY (98.65%), 3 are a HOLD (1.35%).

Gil Blum

Work Performance Price Targets & Ratings Chart

Analyst Gil Blum works at NEEDHAM with a stock forecast success ratio of 25.42% fulfilled within 112.39 days on average. Previously, Gil Blum worked at TRUIST.

Gil Blum’s has documented 416 price targets and ratings displayed on 24 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on AUTL, Autolus Therapeutics Ltd at 17-May-2024.

Wall Street Analyst Gil Blum

Analyst best performing recommendations are on CTIC (CTI BIOPHARMA CORP).
The best stock recommendation documented was for SRPT (SAREPTA THERAPEUTICS) at 10/31/2023. The price target of $82 was fulfilled within 7 days with a profit of $14.69 (21.82%) receiving and performance score of 31.18.

Average potential price target upside

AVRO AVROBIO GBIO Generation Bio Co TSHA Taysha Gene Therapies  FOLD Amicus Therapeutics AUTL Autolus Therapeutics Ltd RCKT Rocket Pharmaceuticals SRPT Sarepta Therapeutics AGLE Aeglea Bio Therapeutics GTHX G1 Therapeutics NRIX Nurix Therapeutics  NXTC NextCure  MREO Mereo BioPharma Group PLC ADR IMAB I-Mab SELB Selecta Biosciences STTK Shattuck Labs  GMDA Gamida Cell Ltd CTIC CTi Biopharma Corp ACLX Arcellx GERN Geron CELC Celcuity LLC CRSP Crispr Therapeutics AG NKTX Nkarta  RXRX Recursion Pharmaceuticals IMCR Immunocore Holdings Ltd

Analyst name


Current price target

Potential Upside

Previous price target


Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score



$0.61 (43.88%)

5 months ago

0/2 (0%)

$0.7 (53.85%)



$0.61 (43.88%)


10 months 5 days ago

0/2 (0%)

$0.59 (41.84%)



$0.61 (43.88%)


10 months 6 days ago

1/3 (33.33%)

$0.57 (39.86%)



1 years 5 months 11 days ago

0/2 (0%)

$13.44 (140.59%)


2 years 1 days ago

0/1 (0%)

$19.05 (212.85%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Gil Blum is most bullish on?

Potential upside of $34.62 has been obtained for SRPT (SAREPTA THERAPEUTICS)

Which stock is Gil Blum is most reserved on?

Potential downside of -$0 has been obtained for GMDA (GAMIDA CELL LTD)

What Year was the first public recommendation made by Gil Blum?

On 2018

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?